Bolt Biotherapeutics, Inc. (BOLT)
After hours:
| Previous close | 1.1000 |
| Open | 1.1200 |
| Bid | 1.0700 x 100 |
| Ask | 1.1400 x 100 |
| Day's range | 1.0500 - 1.1200 |
| 52-week range | 0.8400 - 2.0300 |
| Volume | |
| Avg. volume | 130,140 |
| Market cap | 41.94M |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8300 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.54 |
Simply Wall St.Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
GlobeNewswireBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025 REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapi
- GlobeNewswire
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT) in Boston, Massachusetts. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website
